[go: up one dir, main page]

MX2015017035A - Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis. - Google Patents

Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis.

Info

Publication number
MX2015017035A
MX2015017035A MX2015017035A MX2015017035A MX2015017035A MX 2015017035 A MX2015017035 A MX 2015017035A MX 2015017035 A MX2015017035 A MX 2015017035A MX 2015017035 A MX2015017035 A MX 2015017035A MX 2015017035 A MX2015017035 A MX 2015017035A
Authority
MX
Mexico
Prior art keywords
receptor agonist
bile acid
further compound
signalling inhibitor
tgr5
Prior art date
Application number
MX2015017035A
Other languages
English (en)
Inventor
Anton Egbert Peter Adang
Mark De Boer
Marielle Marie Guillaume Louis Thewissen
Original Assignee
Fast Forward Pharmaceuticals B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fast Forward Pharmaceuticals B V filed Critical Fast Forward Pharmaceuticals B V
Publication of MX2015017035A publication Critical patent/MX2015017035A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un inhibidor de la señalización de CD40 y un compuesto adicional para usarse en el tratamiento de enfermedad inflamatoria crónica en un individuo en necesidad del mismo, en donde el compuesto adicional es un ácido lábil, un derivado de ácido lábil, un agonista del receptor TGR5, un agonista del receptor FXR o una combinación de los mismos. También se proporciona un inhibidor de la señalización de CD40 y un compuesto adicional para usarse en la prevención de cáncer y/o fibrosis, en donde el compuesto adicional es un ácido lábil, un derivado de ácido lábil, un agonista del receptor TGR5, un agonista del receptor FXR o una combinación de los mismos.
MX2015017035A 2013-06-13 2014-06-13 Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis. MX2015017035A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13171913 2013-06-13
PCT/NL2014/050390 WO2014200349A1 (en) 2013-06-13 2014-06-13 Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.

Publications (1)

Publication Number Publication Date
MX2015017035A true MX2015017035A (es) 2016-04-25

Family

ID=48607146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015017035A MX2015017035A (es) 2013-06-13 2014-06-13 Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis.

Country Status (9)

Country Link
US (1) US20160151486A1 (es)
EP (1) EP3008091A1 (es)
JP (1) JP2016521744A (es)
KR (1) KR20160034893A (es)
CN (1) CN105636984A (es)
AU (1) AU2014278833A1 (es)
CA (1) CA2914924A1 (es)
MX (1) MX2015017035A (es)
WO (1) WO2014200349A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160271149A1 (en) * 2015-03-16 2016-09-22 Epinova Therapeutics Corp. Therapeutic compounds that suppress protein arginine methyltransferase activity for reducing tumor cell proliferation
KR20180124123A (ko) * 2016-03-28 2018-11-20 인터셉트 파마슈티컬즈, 인크. Fxr 효능제 및 arb의 조합에 의해 얻어지는 의약
CN112752578B (zh) * 2018-09-25 2024-09-20 宜昌人福药业有限责任公司 作为免疫调节剂的tgr5信号传导的调节剂
CN114945560B (zh) 2019-10-07 2024-08-13 卡尔优普公司 Gpr119激动剂
CN115667277A (zh) 2020-02-28 2023-01-31 卡尔优普公司 Gpr40激动剂
UY39222A (es) 2020-05-19 2021-11-30 Kallyope Inc Activadores de la ampk
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN115569130B (zh) * 2022-10-09 2024-02-09 东莞广州中医药大学研究院 环氧广藿香烯及其组合物在制备预防和/或治疗非酒精性脂肪肝药物中的应用
WO2025162423A1 (zh) * 2024-02-02 2025-08-07 杭州先为达生物科技股份有限公司 针对glp-1r、gipr和gcgr的三激动剂

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
CA2137558A1 (en) 1992-07-17 1994-02-03 Wayne A. Marasco Method of intracellular binding of target molecules
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
KR100663319B1 (ko) 1997-04-14 2007-01-02 마이크로메트 에이지 인간 17-1에이항원에 대해 특이성을 갖는 인간항체 및 그용도
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7138390B2 (en) 2001-03-12 2006-11-21 Intercept Pharmaceuticals Steroids as agonists for FXR
WO2004067008A1 (ja) 2003-01-28 2004-08-12 Takeda Pharmaceutical Company Limited 受容体作動薬
EP2149585B1 (en) * 2003-11-04 2013-08-14 Novartis Vaccines and Diagnostics, Inc. Use of antagonistic anti-CD40 monoclonal antibodies
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
KR20080073725A (ko) * 2005-11-01 2008-08-11 노파르티스 아게 항-ｃｄ40 항체의 용도
CN101395170A (zh) 2006-02-14 2009-03-25 英特塞普特药品公司 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
EP1854810A1 (en) * 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
WO2008002573A2 (en) 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
EP2112995B1 (en) 2007-01-19 2013-07-31 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as tgr5 modulators and methods of use thereof
CN105037476B (zh) 2008-07-30 2018-06-12 英特塞普特医药品公司 Tgr5调节剂及其使用方法
EP2376519B1 (en) 2008-11-19 2013-11-13 Intercept Pharmaceuticals, Inc. Tgr5 modulators and method of use thereof
ES2592452T3 (es) 2008-11-19 2016-11-30 Intercept Pharmaceuticals, Inc. Moduladores de TGR5 y métodos de uso de los mismos
AU2010242498A1 (en) * 2009-05-01 2011-12-22 Micropharma Limited Bacterial compositions for prophylaxis and treatment of degenerative disease
HUE049849T2 (hu) 2010-03-31 2020-10-28 Boehringer Ingelheim Int Anti-CD40 antitestek

Also Published As

Publication number Publication date
EP3008091A1 (en) 2016-04-20
AU2014278833A1 (en) 2016-01-07
JP2016521744A (ja) 2016-07-25
KR20160034893A (ko) 2016-03-30
WO2014200349A1 (en) 2014-12-18
CN105636984A (zh) 2016-06-01
US20160151486A1 (en) 2016-06-02
CA2914924A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
MX2015017035A (es) Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis.
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
PH12015502091A1 (en) Cdc7 inhibitors
PH12016501702B1 (en) Pyrazole amide derivative
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
EP3030323A4 (en) Kdm1a inhibitors for the treatment of disease
PH12016500024A1 (en) Bromodomain inhibitor
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
EP3256218A4 (en) Kdm1a inhibitors for the treatment of disease
NZ755605A (en) Compositions for modulating tau expression
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX375902B (es) Inhibidores de serina/treonina cinasa.
WO2012125544A3 (en) Necroptosis inhibitors and methods of use therefor
MX2015008813A (es) Composiciones y metodos para contrarrestar la inhibicion del factor xa.
EP2990419A4 (en) Preventive or therapeutic agent for inflammatory disease
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EP3097084A4 (en) New kallikrein 7 inhibitors
MX2016014483A (es) Nuevos compuestos utiles como inhibidores de s100.
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity
PH12016500809B1 (en) Glucopyranosyl - substituted indole-urea derivatives and their use as sglt inhibitors
EP3164195A4 (en) Glutaminase inhibitor therapy
PH12020500472A1 (en) Autotaxin inhibitor compounds